cytomegalovirus

Additional strategies for the prevention of CMV disease are often used for at-risk patient populations, including prophylaxis (eg, administration of antiviral drugs 1 to 4 times daily for 3 to 6 months following transplantation) or viremic monitoring with rapid administration of antiviral medications should the patient demonstrate evidence of viral replication.

13] The disease is diagnosed presumptively by means of fundoscopy, unlike systemic CMV disease, which requires confirmation by biopsy.

Patients who developed clinically significant CMV infection, defined as the onset of CMV disease or initiation of anti-CMV preemptive therapy based on documented viremia (as measured by the central laboratory) and the clinical condition of the patient, discontinued study drug and received anti-CMV preemptive therapy.

Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease.

The primary infection has a subclinical progress or manifests itself as mononucleosis syndrome in a normal host; however, in an immunocompromised host, primary infection may cause severe manifestations with fatal outcomes such as CMV disease (pneumonia, hepatitis, colitis, meningoencephalitis, crescentic glomerulonephritis, pancreatitis) ([9,10]).

These treatments should benefit patients with CMV disease and help prevent the development of birth defects caused by CMV in Wales and beyond.

Preemptive therapy has proved that ganciclovir is useful in reducing risks for late CMV disease, neutropenia, and fungal disease.

Cytomegalovirus (CMV) infection is an important clinical concern after all types of solid organ transplantation, but the highest rates of CMV infection and CMV disease are seen in lung and heart-lung transplant patients [1].

According to the company, T cell immunity against cytomegalovirus (CMV) is a factor in controlling viral latency and susceptibility to CMV disease, which can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients.

1,2] CMV retinitis is the most common manifestation of end-organ CMV disease among patients with AIDS.

Active CMV disease in older patients or in those with compromised immune systems is a devastating disease.

CMV disease is a common source of illness in transplant patients and can cause pneumonia, diarrhea and digestive tract ulcers, or other problems.

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.

According to Roche, professionals use CMV DNA viral load information from the test to help manage patients who have been diagnosed with CMV disease, specifically patients whose immune system has been suppressed for solid organ transplantation.

Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically patients with an immune system that has been suppressed for solid organ transplantation.